Conference Correspondent

Using a novel electronic health record database that included nearly 800 chronic lymphocytic leukemia patients, recent treatment patterns in the United States showed a decline in the use of fludarabine-, bendamustine-, and rituximab-containing regimens and a significant increase in the use of obinutuzumab and ibrutinib, either as monotherapy or in combination regimens.
Heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) derived significant benefit from a combination of daratumumab, dexamethasone, and bortezomib. These data continue to support the addition of daratumumab to a standard-of-care regimen in RRMM.

Administration of the asthma medication montelukast more than 30 minutes before infusion of daratumumab can drastically reduce infusion-related reactions in patients with multiple myeloma.

In a subgroup analysis of the POLLUX trial, daratumumab plus lenalidomide/dexamethasone was associated with superior progression-free survival and response rates versus lenalidomide/dexamethasone alone among patients who were previously treated with bortezomib or who were bortezomib-refractory or lenalidomide-naïve.

Clinical outcomes were better when daratumumab was added to a regimen of patients with relapsed/refractory multiple myeloma who received prior therapy.
Pharmacokinetic analysis of daratumumab as part of combination regimens identified no clinical or demographic characteristics that altered exposure and activity of the monoclonal antibody. The findings support the body-weight–based dosing of 16 mg/kg.
Data from a “real-world” historical cohort of heavily pretreated patients in the Czech Republic confirmed the benefits shown in clinical trials of single-agent daratumumab compared with treatment by physician’s choice.
As out-of-pocket costs continue to rise, patients and healthcare stakeholders are increasingly concerned about the relative value of different treatment options. This claims-based analysis assesses trends in novel therapy use, total healthcare costs, and survival outcomes among newly diagnosed multiple myeloma patients in the United States since 2000.

Unmet treatment needs remain in multiple myeloma, particularly among patients with relapsed/refractory disease who have received multiple lines of therapy. This study evaluates a potential salvage approach of daratumumab-based retreatment in patients refractory to daratumumab and/or pomalidomide.

Risk stratification tools are frequently used to help guide treatment decisions after first relapse in multiple myeloma. Researchers have developed a new risk stratification tool consisting of 4 distinct dimensions that is used to characterize survival expectations.

Page 4 of 11
Results 31 - 40 of 101